Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer

International Journal of Medical Sciences

Volumn 10, Issue 7, 2013, Pages 932-937

  Zafra Ceres, Mercedes ^a   de Haro, Tomas ^a   Farez Vidal, Esther ^b   Blancas, Isabel ^a   Bandres, Fernando ^c   de Dueñas, Eduardo Martinez ^d   Ochoa Aranda, Enrique ^d   Gomez Capilla, Jose A ^a,b   Gomez Llorente, Carolina ^e  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b Department of Biochemistry and Molecular Biology III and Immunology ^*  (Spain)

^c Breast Pathology Center   (Spain)

^d HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

^e UNIVERSITY OF GRANADA   (Spain)

Author keywords

CYP2C19; CYP2D6; Endoxifen; Estrogen positive breast cancer; Genetic diagnosis; Tamoxifen

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; ENDOXIFEN; ESTROGEN RECEPTOR; NORTAMOXIFEN; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYP2C19 GENE; CYP2D6 GENE; DRUG BLOOD LEVEL; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PILOT STUDY; POPULATION RESEARCH; SPANISH; TUMOR GENE;

CYP2C19; CYP2D6; ENDOXIFEN; ESTROGEN-POSITIVE BREAST CANCER; GENETIC DIAGNOSIS; TAMOXIFEN;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; POLYMORPHISM, GENETIC; SPAIN; TAMOXIFEN;

EID: 84878958399     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.5708     Document Type: Article

References (36)

1. Russell RC. Bailey and Lovés short practice of surgery. In: Chapter on breast cancer; 23rd ed. London: Arnold. 2000.
2. Del Re M, Michelucci A, Simi P, et al. Pharmacogenetics of anti-estrogen treatment of breast cancer. Cancer. Treat. Rev. 2012; 38: 442-450.
3. O'Donnell PH, Ratain MJ. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol. Oncol. 2012; 6: 251-259.
4. Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: Molecular Genetics, interethnic differences and clinical importance. Drug. Metab. Pharmacokinet. 2012; 27: 55-67.
5. Abraham JE, Maranian MJ, Driver KE, et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast. Cancer. Res. 2010; 12: R64.
6. Kelly CM, Pritchard KI. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J. Natl. Cancer. Inst. 2012; 104: 427-428.
7. Rideg O, Háber A, Botz L A, et al. Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population. Cell. Biochem. Funct. 2011; 29: 562-568.
8. Singh MS, Francis PA, Michael M. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast. 2011; 20:111-118.
9. Ingelman-Sundberg, M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacolo. Ther. 2007; 116: 496-526.
10. Fernandez-Santander A, Luna F, Santiago C, et al. CYP2D6 polymorphism screening in a selected population of Spain (La Alpujarra): no effect of geographical isolation. Ann. Hum. Biol. 2010; 37:267-273.
11. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002; 3: 229-243.
12. De Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006; 47: 75-85.
13. Lammers LA, Mathijssen RHJ, Gelder T van, et al. Impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer. 2010; 103: 765-771.
14. Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012; 104: 452-460.
15. Nakamura Y, Ratain MKJ, Cox NJ, et al. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine- responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012; 104: 1264.
16. Regan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine- responsive breast cancer: The breast International Group 1-98 trial. J Natl Cancer Inst. 2012; 104: 441-451.
17. Lyon EG, Gastier FJ, Palomaki GE, et al. Laboratory testing of CYP2D6 alleles in relation to tamoxifen theraphy. Genet Med. 2012; 14: 990-1000.
18. González I, Perez Picañol B, Alvarez M, et al. Study of debrisoquine hydroxylation polymorphism (CYP2D6) in the Cuban population compared to Spaniards. Med Clin (Barc). 2007; 128: 772-774.
19. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 2006; 57: 119-137.
20. Bernard S, Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphism of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006; 11: 126-135.
21. Menoyo A, Del Rio E, Baiget M. Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell. Biochem. Funct. 2006; 24: 381-385.
22. Sachse C, Brockmöller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 1997; 60: 284-295.
23. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997; 7: 193-202.
24. Ramón y Cajal T, Altés A, Paré L, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat. 2010; 119: 33-38.
25. Rebsamen MC, Desmeules J, Daali Y, et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009; 9:34-41.
26. Fuselli S, Dupanloup I, Frigato E. Molecular diversity at CYP2D6 locus in the Mediterranean region. Eur J Hum Genet. 2004; 12: 916-924.
27. Sistonen J, Sajantila A, Lao O, et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenetics and Genomics. 2007; 17: 93-101.
28. Farez-Vidal ME, Gomez-Llorente C, Blanco S, et al. Multimutational analysis of eleven cystic fibrosis mutations common in the Mediterranean areas. Clin. Chem. 2004; 50: 2155-2157.
29. Farez-Vidal ME, Gandia-Pla S, Blanco S, et al. Multi-mutational analysis of fifteen common mutations of the glucose 6-phosphate dehydrogenase gene in the Mediterranean population. Clin. Chim. Acta. 2008; 395: 94-98.
30. Schorth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 2007; 25: 5187-5193.
31. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-1436.
32. Lim JS, Chen XA, Singh O, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br. J. Clin. Pharmacol. 2011; 71: 737-750.
33. Serrano D, Lazzeroni M, Zambon CF, et al. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian tamoxifen prevention trial. Pharmacogenomics. J. 2011; 11: 100-107.
34. Ruiter R, Bijl MJ, van Schaik RH, et al. CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics. 2010; 11: 1367-1375.
35. Van Schaik RH, Kok M, Sweep FC, et al. The CYP2C19*2 genotyped predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics. 2011; 12: 1137-1146.
36. Barginear MF, Jaremko M, Peter I, et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther. 2011; 90: 605-611.